Vitamin D3 and Its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

M. Rita I. Young* and David D. Walker
Ralph H. Johnson VA Medical Center, Charleston, Department of Otolaryngology – Head and Neck Surgery Medical University of South Carolina, Charleston USA

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) is the 6th most common type of malignancy worldwide, and represents over 6% of the global cancer burden. Each year, HNSCC accounts for nearly 650,000 new cases of cancer, and over 35,000 deaths worldwide. Historically, HNSCC has been a challenging disease to manage, with locally advanced disease often requiring a multidisciplinary approach of surgery, chemotherapy and radiation. However, despite significant advances among the aforementioned fields, the current 5-year survival rate of approximately 50% has improved very little over the last 30 years. This poor improvement in prognosis is a reflection of the unique treatment challenges presented by HNSCC, which include advanced stages at diagnosis, high recurrence rate after surgical removal and second primary tumor development. Moreover, not only are current treatment options often non-curative, but they are associated with significant morbidity, including substantial physical deformity and functional deficits. Together, these challenges underscore the importance of developing novel anti-neoplastic treatment strategies which may improve survival and quality of life among HNSCC patients.

One of the more intriguing novel anti-neoplastic agents is 1α,25-dihydroxyvitamin D3 ([1,25(OH)2D3], calcitriol], the hormone first identified as an effective treatment for rickets, which has recently garnered wide-spread support as a possible anti-neoplastic agent in a number of different cancer subtypes. Epidemiological observational studies, performed mainly in the United States, have long postulated a correlation between higher latitude residence and overall cancer incidence and mortality. The first such theory was put forth in 1937 by Peller and Stephenson, who together hypothesized that increased sunlight exposure lowered the risk of cancer. Four years later, observational studies defined the relationship further, demonstrating a significant association between geographic latitude and cancer mortality. Since that time, scientists have continued to hypothesize that inadequate serum vitamin D levels at higher latitudes increases one’s risk for a number of different cancers including colon, breast, prostate and ovarian cancers. Large cohort studies have

*Corresponding Author
confirmed similar findings among HNSCC patients as well. Such studies have not only
demonstrated significantly reduced 25-hydroxyvitamin D [25(OH)D] serum levels among
HNSCC patients, but also found disease-free survival time to be significantly associated
with 25(OH)D serum levels 12.

However, a definitive causal relationship is perhaps not as clear as it seems. Though these
reports have evoked widespread enthusiasm within the scientific community, such zeal has
remained tempered. Most of the data regarding an association between 25(OH)D and cancer
is derived from retrospective ecological observational studies. To date, no large-scale
randomized control trials have ever been done examining serum 25(OH)D levels and a
primary outcome of cancer. In fact, smaller randomized control studies are extremely
limited and yield conflicting results as to the significance of this relationship 13. There are
several prospective studies examining the relationship, but such studies have offered no
consensus findings regarding the association 14, 15.

The continued optimism regarding vitamin D’s role as an anti-neoplastic agent is sustained,
however, by a number of molecular studies which support the biologic feasibility of the
theory. In particular, proponents cite the widely expressed vitamin D receptor (VDR), which
to date has been found in over 30 different human tissues including lymphocytes, muscle,
skin and cancer cells 16, 17. Furthermore, the terminal enzyme in the synthesis of active
Vitamin D, 1-α-hydroxylase, also exhibits widespread expression allowing for synthesis of
the hormonally active metabolite in a number of different cell types. Not only is vitamin D
capable of ubiquitous synthesis and action, but in vivo studies within both human and
animal models suggest that the active metabolite of vitamin D (calcitriol) is capable of
eliciting a number of non-calcemic downstream effects. Many of these actions can be
considered anti-neoplastic in nature, including anti-inflammatory, proapoptotic, and
antiangiogenic properties, the promotion of cell differentiation, and the inhibition of cancer-
cell proliferation.

In this chapter we describe the relevant molecular and biological mechanisms regarding
Vitamin D metabolism. We also describe the basic and inherent anti-cancerous properties of
vitamin D metabolites, with a specific emphasis on its role in the management of HNSCC.

2. Overview of vitamin D biological activity

In 1919, Sir Edward Mellanby conducted a series of elegantly designed experiments on
rachitic canines. By placing strict restrictions on both diet and sunlight exposure, he was
able to establish a causal relationship between the bone disease rickets and a deficiency of
an unidentified trace dietary substance. Mellanby concluded, at that time, that the unknown
entity was most likely a previously undescribed fat-soluble vitamin. It was not until 1932,
however, that Vitamin D’s chemical structure was formally characterized, revealing that
Vitamin D was not actually a vitamin, but a steroid hormone. In the late 1960s it was
discovered that vitamin D was actually a precursor of a new steroid hormone, 1,25(OH)2D3,
produced intrarenally. As both the physical structure and physiologic actions of
1,25(OH)2D3 continued to be better characterized, it was soon found to be a critical
component of both calcium homeostasis and overall bone health. As research progressed
into the 21st century, scientists discovered that the hormone impacted a number of
important non-calcemic cell regulatory functions.
Today, what is commonly referred to as “Vitamin D” is actually a combination of ergocalciferol (vitamin D$_2$) and cholecalciferol (vitamin D$_3$). Both compounds are readily available in diet form, with vitamin D$_2$ being found in plant products and vitamin D$_3$ found predominately in fatty fish, fish liver oil, and eggs with smaller amounts found in cheese and meat products. In either case, the total amount of either vitamin found within food items is relatively small; thus, many developed countries, including the United States, have turned to fortifying numerous food items, such as milk and juices, with both vitamin D$_2$ and vitamin D$_3$. Despite food fortification, diet is not the body’s primary means for acquiring vitamin D$_3$ stores. Instead, the majority of the body’s cholecalciferol is synthesized in vivo through a photosynthetic process occurring in the epidermal layer of sun-exposed skin. Upon exposure to ultraviolet radiation, the epidermis is capable of transforming a cholesterol derivative (7-dehydrocholesterol) into vitamin D$_3$ (cholecalciferol). The catalysis, however, is not uniform among all populations and is subject to significant and intense variations based on skin pigmentation, sunscreen use, age, gender and even obesity.

After synthesis, cholecalciferol enters the blood stream and is transported to the liver. There it undergoes intra-hepatic hydroxylation at the 25 position to create 25-hydroxyvitamin D$_3$ [25(OH)D$_3$ or calcidiol]. 25(OH)D$_3$ is the circulating form of the hormone within the plasma as well as the most accurate biomarker of overall Vitamin D3 status. 25(OH)D$_3$ is next catalyzed into one of two metabolites: the biologically inert 24,25-dihydroxyvitamin D$_3$ [24,25(OH)$_2$D$_3$] or the biologically active metabolite 1,25-dihydroxyvitamin D$_3$ [1,25(OH)$_2$D$_3$]. Exactly which metabolite is created depends entirely on what enzyme is expressed within the local tissue. If the tissue expresses 24-hydroxylase (also known as CYP24A1), then 25(OH)D$_3$ is modified to become 24,25(OH)$_2$D$_3$. This particular metabolite has poor affinity and avidity toward the VDR and is considered the first step in vitamin D decomposition. Alternatively, if the tissue expresses 1-α hydroxylase (also known as CYP27B1), the biologically active metabolite 1,25(OH)$_2$D$_3$ is formed. This particular metabolite is most well known for its regulation of calcium homeostasis and is the metabolite capable of exerting anti-neoplastic effects on cancer cells.

3. Vitamin D mechanism of action

The majority of Vitamin D’s hormonal action involves direct interaction with a single VDR. An intranuclear regulator of gene transcription, the VDR is a member of the class II steroid hormone receptors and is closely related to the retinoic acid and thyroid hormone receptors. The human receptor is located on chromosome 12q12q14 and consists of nine exons. Fully transcribed, the receptor is a 427-amino acid peptide with relatively simple binding configuration consisting of a DNA-binding domain termed the C-domain, a ligand-binding domain called the E-domain and an activating domain called the F-domain. The receptor acts by interacting with portions of DNA called vitamin D-responsive elements (VDREs). Located in the promoter region of target genes, VDREs are commonly found within 1 kilobase from the gene start sequence. Such areas are composed of hexanucleotide repeats separated by 3 nonspecified nucleotide bases (for example CGACTA-NNN-CGACTA where N represents any nucleotide).

Once 1,25(OH)$_2$D$_3$ is transported into the cell, it enters the nucleus where it is capable of binding to VDR. After binding, the 1,25(OH)$_2$D$_3$-VDR complex synergistically
Squamous Cell Carcinoma

heterodimerizes with retinoid-X receptor (RXR). The 1,25(OH)\textsubscript{2}D\textsubscript{3}-VDR-RXR complex then binds specifically to a VDRE sequence complex, with the VDR occupying the 3’ region and the RXR positioned at the 5’ end. Conformational changes which occur after 1,25(OH)\textsubscript{2}D\textsubscript{3} binding results in the release of corepressors and the simultaneous exposure of binding sites for transcriptional coactivators. VDR coactivators are then capable of binding the complex, which results in the acetylation and subsequent release of histones from the DNA strand. Without histones in place, the appropriate transcription factors are capable of binding to the naked DNA strand and transcription of the target gene is able to initiate.

Certain variables that construct this transcriptional machinery apparatus may have a direct role within the formation of cancer. Recent resequencing of VDR gene identified 194 single-nucleotide polymorphisms (SNPs). It has been hypothesized that VDR SNPs themselves may have a direct impact on formation and prognosis of certain types of cancer, including HNSCC. The two most widely investigated receptors regarding their impact and role within cancer include a FokI restriction fragment-length polymorphism (RFLP) in exon 2 and an adjacent TaqI RFLP in exon 9. These two polymorphisms were recently investigated with respect to their association with HNSCC incidence. Such studies yielded mixed results. Findings from one study demonstrated that the heterozygous genotype of TaqI (Tt) polymorphism may be associated with an increased susceptibility to HNSCC. In a separate study, however, both homozygous variant genotypes, TaqI (tt) and FokI (ff), were associated with a reduced risk of HNSCC as compared to the more common TaqI (TT) and FokI (FF) genotypes. Thus, it remains uncertain as to whether or not specific VDR SNPs provide a protective or deleterious effect regarding HNSCC risk. However, demonstrations of both increased and decreased HNSCC risk warrant continued research into how VDR SNPs may not only impact cancer incidence, but also mortality and treatment response.

3.1 Biological plausibility within cancer

The general biologic characteristics and mechanisms of action detailed above presented two main molecular hurdles for scientists considering 1,25(OH)\textsubscript{2}D\textsubscript{3} as a plausible anti-neoplastic agent. First, there was the seemingly restricted localization of 1-\(\alpha\) hydroxylase. The enzyme responsible for converting vitamin D into its active form is highly expressed in renal proximal tubules and was once thought to be solely expressed intra-renally. However, it is now known that many non-renal cells, including bone, placenta, prostate, keratinocytes, macrophages, T-lymphocytes, dendritic cells and several cancer cells all express the converting enzyme capable of producing the hormonally active metabolite 1,25(OH)\textsubscript{2}D\textsubscript{3}. This particular formation of Vitamin D contains a high affinity for the VDR and is capable of eliciting an anti-neoplastic response. It is this formation with which we concern ourselves for the remainder of the discussion.

The second major impasse was the restrictive localization of VDR to skeletal tissues. However, since VDRs were first discovered their localization has been confirmed on a variety of tissues. With respects to SCC, it has been demonstrated that not only do human cancer cell lines (SCL-1, SCL-2) exhibit VDR expression, but in fact they express the receptor in higher amounts than normal human skin cell lines. The discovery of extra-renally expressed 1-\(\alpha\) hydroxylase and extra-skeletally expressed VDR was paramount in vitamin D’s acceptance as a possible anticancer agent. Such findings sustained the molecular
integrity of the theory, paving the way for the initiation of many phase I and phase II clinical trials.

4. Vitamin D and cancer

Thus far, 1,25(OH)_2D_3 has been presented as a secosteroid whose fundamental intra-nuclear action is critical for appropriate regulation of calcium homeostasis and proper bone mineralization. Vitamin D, however, has other non-calcemic regulatory functions, including many which make it an intriguing anti-neoplastic agent. Four separate cellular functions tend to be compromised in order for cancer to thrive within a normal host environment: 1) aberrant regulation of differentiation, 2) dysregulated cellular proliferation, 3) newly acquired ability permitting invasion and metastasis, 4) dysregulated cell destruction of altered self-cells. Numerous published reports have demonstrated that 1,25(OH)_2D_3 is capable of restoring or repairing each of the aforementioned hallmarks of carcinogenesis. It does so in a number of ways, including inhibition of cellular proliferation, disruption and inhibition of angiogenesis, promoting apoptosis, and improving tumor immunosurveillance.

4.1 Cellular proliferation and differentiation

The processes of cellular proliferation and differentiation are intimately intertwined, and the aberrant regulation of each is critically important to the prosperity of growing cancer cells. The normal cell grows along a continuum of cellular differentiation. As a cell proceeds toward terminal differentiation, its ability to divide and proliferate is decreased. This feature is exploited and utilized by many newer anti-neoplastic agents, including 1,25(OH)_2D_3. A promising feature of 1,25(OH)_2D_3 is its ability to manipulate the cell’s state of differentiation. In vitro studies in human cell lines demonstrated that 1,25(OH)_2D_3 is capable of reducing cell proliferation by inducing cell cycle arrest in G0/G1 phase while simultaneously promoting cellular differentiation.

These results were replicated within murine SCC cell lines which showed that administration of 1,25(OH)_2D_3 to cells induces G0/G1 cell-cycle arrest via the transcriptional activation of CDKN1B and subsequent dephosphorylation of pRB. The study demonstrated that in both in vivo and in vitro studies, the increases seen in CDKN1B were the result of downregulated p21 activity, a potent CDK inhibitor. Human SCC cell lines that positively express VDR showed a potent decrease in cellular proliferation when exposed to 1,25(OH)_2D_3 and its analogues. Vitamin D’s ability to force cells into differentiation may be of critical importance, as such actions can aid in the inhibition of tumor cell proliferation.

4.2 Angiogenesis

Cancer cells will often acquire the ability to escape the confines of the original tumor nidus. The tumor cell often relies heavily on its angiogenic properties to spread. In theory, limiting the tumor’s ability to aberrantly generate rogue blood supplies may limit its ability to thrive and metastasize, offering a potential avenue to achievement of loco-regional control. Several studies have demonstrated that 1,25(OH)_2D_3 contains potent antiangiogenic properties capable of reducing the invasiveness of cancer cells. In vitro studies demonstrated that...
1,25(OH)$_2$D$_3$ and its analogs directly inhibit tumor-derived endothelial cell proliferation in addition to disrupting angiogenic signaling in cancer cells.  

Within HNSCC cell-lines, treatment with 1,25(OH)$_2$D$_3$ resulted in a significantly lower production of pro-angiogenic cytokines, VEGF and PDGF. Meanwhile, the pro-inflammatory and proangiogenic cytokine, IL-8, exhibits no change after administration of 1,25(OH)$_2$D$_3$. The finding of decreasing concentrations of VEGF has prompted considerable interest, as it has not only been cited as a marker for tumor metastasis, but also used as a prognostic factor in HNSCC patients.

4.3 Apoptosis

Apart from its actions on the cell cycle, 1,25(OH)$_2$D$_3$ can also suppress cancer growth via induction of apoptosis. Results carried out on human HNSCC cell lines demonstrated that exposure to 1,25(OH)$_2$D$_3$ results in the downregulation of several anti-apoptotic genes. In particular, 1,25(OH)$_2$D$_3$ represses the expression of the anti-apoptotic, pro-survival gene BCL-2 while simultaneously increasing pro-apoptotic gene products of BAX and BAK. Studies completed on mouse SCC tumor cells with 1,25(OH)$_2$D$_3$ revealed a form of caspase-dependent apoptosis involving the growth-promoting/pro-survival signaling molecule, mitogen-activated protein kinase kinase (MEK). The study was able to demonstrate that exposure to 1,25(OH)$_2$D$_3$ resulted in increased VDR expression and concomitant cleavage of the pro-survival signaling molecule MEK via a caspase-dependent manner.

4.4 Immune escape

Key to the survival of cancer cells is the evasion of destruction, a critically fundamental step of which is the ability to evade the immune system. HNSCC, like all cancers, is capable of evading the host’s immune system via a number of different mechanisms. Cancer can evade antigenic recognition via tissue sequestration, improper lymphocytic homing due to improper expression of adhesion molecules, and antigenic shedding and modulation. In certain instances, however, antigenic recognition remains intact, despite a poor immune response. In such cases, cancers continue to thrive by releasing immunosuppressive cytokine, downregulating MHC I complex, or instilling dysregulated or improper costimulation.

Numerous studies performed on HNSCC patients have investigated the effects of 1,25(OH)$_2$D$_3$ on the immune profile of patients. Within the past 10 years, it has been shown that not only do monocytes, B-cells, and T-cells express VDR, but also contain the enzyme 1-$\alpha$-hydroxylase capable of converting 25(OH)D$_3$ into 1,25(OH)$_2$D$_3$. Such findings confirmed long-standing speculation that vitamin D is critical for the appropriate management and integrity of the immune system. Numerous studies have since attempted to understand exactly how vitamin D modulates the host immune profile.

HNSCC itself is associated with profound immunosuppression. This is in part due to tissue infiltration by immunosuppressive immature progenitor cells with surface marker CD34. In one study, HNSCC patients treated with 1,25(OH)$_2$D$_3$ exhibited decreased levels of intratumoral CD34$^+$ cell populations and diminished the preexisting profound
immunoinhibitory effect of the cancer. Such findings suggest that 1,25(OH)₂D₃ may be helpful in overcoming the profound immunosuppression associated with HNSCC. Tissues of HNSCC patients who received treatment with 1,25(OH)₂D₃ contained increased levels of CD4⁺ cells and, more significantly, CD8⁺ T cells. Such findings indicate an increased infiltration of immune effector cells into the tumor microenvironment. Also prominent was an increase in cells expressing the lymphoid activation marker CD69, which represent mainly T cells and monocytes. The same study showed that HNSCC patients who received 1,25(OH)₂D₃ prior to treatment had a lengthier time to tumor recurrence compared with patients who were not treated before surgery. The treatment arm exhibited a median time to recurrence that was almost 3.5-fold longer than control patients who were untreated before surgery. These findings are complemented by separate studies suggesting that treatment with 1,25(OH)₂D₃ may be an appropriate method of restarting the immune system.

5. Future clinical considerations

One of the most discussed aspects regarding the implementation of vitamin D as an anti-cancer medication is dosing regimen. The Institute of Medicine recently addressed vitamin D dosing regimens in its newly published Dietary Reference Intakes for Vitamin D. Their review of the literature yielded the suggested dietary intake of 600 IU per day for persons 1 to 70 years of age and 800 IU per day for persons over 70. Such intakes corresponded to serum 25(OH)D levels of at least 20 ng per milliliter (50 nmol per liter) with recommended daily ingestion not to exceed 4000 IU per day. The same review concluded that the prevalence of vitamin D deficiency in North America, which previously published reports had suggested to be as high as 54% in some populations, has been drastically overestimated. The authors concluded that the vast majority of North American individuals have serum 25(OH)D concentrations above 20 ng per milliliter, which is adequate for bone health in at least 97.5% of the population.

Another area of debate is the concept of vitamin D screening as a predictor for cancer incidence. Since its inception, many have disagreed with such practices. One of the main areas of contention rests in the number of confounding variables associated with low serum 25(OH)D levels. These variables, which include obesity, lack of physical activity, and poor diet or supplementation practices, have the ability to impact cancer risk. Critics also cite reverse-causation bias, noting that in certain individuals poor health reduces one’s ability to participate in outdoor activities, resulting in lower vitamin D levels.

6. Conclusion and future perspective

It is the opinion of the authors that the role of 1,25(OH)₂D₃ as an anti-cancer agent warrants continued clinical and laboratory exploration. Further investigation into the relationship calls for randomized control trials of vitamin D for cancer prevention. As noted by the recently published IRAC review, observational studies themselves are unlikely to “disentangle the complex relationships between vitamin D and known cancer risk factors.” Such reports, however, have paved the way for numerous ongoing phase I and II clinical trials which should begin to elucidate what role, if any, 1,25(OH)₂D₃ may play in the treatment of HNSCC.
7. References


This book points to some new areas for investigation on squamous cell carcinoma (SCC). Firstly, the features and management of some specific SCC is discussed to give the readers the general principles in dealing with these uncommon and sophisticated conditions. Some new concepts in adjuvant therapy including neoadjuvant therapy and gold nanoparticle-based photodynamic therapy are introduced. Secondly, a detailed discussion of molecular aspects of tumor invasion and progression in SCC is provided with the emphasis on the roles of some important factors. The role of tumor microenvironment in head and neck SCC is specifically discussed. Thirdly, the roles of cancer stem cells (CSC) in cancer therapy of SCC are described. Molecular mechanisms involving therapeutic resistance and new therapeutic strategies targeting CSC are discussed in detail. Finally, other aspects concerning SCC are included, which involve the assessment, genetic manipulation and its possible clinical implications for the treatment of SCC.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
